In summary, we provided evidence and rationale supporting preclinical assessment of the novel combinational targeted therapy for human CML and posited SOS1 PROTAC SIAIS562055 as a promising candidate for enhancing the therapeutic efficacy of BCR–ABL inhibitors. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.